Sorrento subsidiary to develop ADC cancer therapies

By The Science Advisory Board staff writers

February 8, 2021 -- Sorrento Therapeutics has formed a subsidiary company called Adnab that will develop and commercialize a Mayo Clinic-developed technology platform for the manufacture of antibody-drug conjugates (ADC), each called an Adnab.

An Adnab is an immune complex of nanoparticle albumin-bound drug products, such as nab-paclitaxel, that are noncovalently conjugated with tumor-targeting monoclonal antibodies (mAbs), the firm said. The products will use Sorrento's G-MAB library of fully humanized mAbs to generate a portfolio of product candidates to target liquid and solid tumors with the potential to treat autoimmune diseases as well.

Dr. Svetomir Markovic, PhD, at the Mayo Clinic spearheads the project, and to date has formed nine potential Adnab candidates, including two that will be investigated in a U.S. Food and Drug Administration (FDA) supervised, investigator-initiated human trial. The company plans to file multiple investigational new drug (IND) applications this year; it also plans to request breakthrough therapy designation from the FDA in both ovarian and endometrial cancers.

Henry Ji, PhD, is Adnab's chairman and CEO.

Sorrento to file IND for anti-SARS-CoV-2 nasal drops
Sorrento Therapeutics is filing an investigational new drug application (IND) with the U.S. Food and Drug Administration for its STI-2099 (Covi-Drops),...
Sorrento plans phase II trial for COVID-19 treatment
Sorrento Therapeutics received clearance from the U.S. Food and Drug Administration to initiate a phase II clinical trial evaluating abivertinib for treatment...
Sorrento moves forward with COVID-19 prophylactic drug
Sorrento has completed preclinical testing of STI-4398 (COVIDTRAP), reporting positive results on the protein's ability to neutralize and inhibit the...
Sorrento, Mount Sinai to develop targeted SARS-CoV-2 antibody treatment
Sorrento Therapeutics and Mount Sinai Health System have joined forces to develop an antibody therapy called COVI-Shield to treat COVID-19.

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter